欢迎来到天天文库
浏览记录
ID:33990939
大小:4.98 MB
页数:47页
时间:2019-03-03
《乳腺癌新辅助化疗前er、pr、her-2、p53、ki67表达与术后miller & payen分级的相关性》由会员上传分享,免费在线阅读,更多相关内容在学术论文-天天文库。
1、万方数据摘要目的探讨乳腺癌新辅助化疗(NAC)前后,ER、PR、HER-2、Ki一67、P53变化及病理MP分级与新辅助化疗疗效之间的差异。方法收集山东省聊城市人民医院2009年1月至2012年12月施行乳腺癌新辅助化疗的210例。新辅助化疗前均行穿刺活检。2—4周期化疗结束实施效果评估再行乳腺癌根治术或保乳术。新辅助化疗前后均对乳腺原发灶进行临床体检、乳腺X线检查,依实体瘤的疗效评价标准(RECIST,1.1版)对乳腺癌原发灶进行临床疗效评价,依Miller和Payne(MP)分级系统进行病理评价。结果(1
2、)210{歹EJ经NAC后,完全缓解33例,部分缓解124{歹0,疾病稳定42例,疾病进展11例。总有效率为74.7%;(2)MP分级:1级13例、2级35ff0、3级30例、4级87例和5级45例;(3)NAC对ER、一PR、HER-2、Ki-67及P53的表达状态无影响。ER、HER一2、P53阴性表达者有效率与阳性者差异有统计学意义(P3、辅助化疗的临床评价与病理评价存在统计学相关性。硕士研究生:范兴哲(法医学)指导教师:赵鹏教授关键词:乳腺癌;新辅助化疗;疗效评价2万方数据AbstractIUllIIlUIlllIlllUIY2738629ObjectiveToinvestigatethedifferencesbetweenbreastcancerneoadjuvantchemotherapy(NAC)beforeandafter,withintheparameterofER,PR,HER一2,飚一67,P53andpathologicalc4、hangesingradingMPMethodsWecollecttheimplementationof210casesofbreastcancertoneoadjuvantchemotherapyinShandongLiaochengPeople‘SHospitalfromJanuary2009toDecember2012.BeforeneoadjuvantchemotherapyunderwentcoreneedlebiopsyAfter2-4cyclesofchemotherapywetraderadi5、calmastectomyorbreast·conservingsurgery.Bothbeforeandafterneoadjuvantchemotherapyforbreastprimarytumorclinicalexamination,breastx—rayexamination,accordingtotheResponseEvaluationCriteriainSolidTumors(RECIST,version1.1)oftheprimarytumorinbreastcancerclinicale6、valuationofefficacy.Inthesametime,weevaluatethepathologicalefficacyaccordingtoMillerandPayne(MP)gradingsystem.Results1)210casesafterNAC,completeremission3cases,124casesofpartialremission,stablediseasein42cases,11casesofdiseaseprogression.Thetotaleffectivera7、teWas74.7%.2)MPclassification:13cases1,35cases2,30cases3,87cases4and45cases5.3)NACforER,PR,HER-2,Ki一67andP53expressionstatushasnoeffect.ER,HER-2,P53negativeexpressionefficiencyandpositivedifferenceWasstatisticallysignificant(P<0.05).4)Clinicalbreastexaminat8、ionandX-rayexaminationofrelevantclinicalandpathologicalevaluationofastatisticalevaluationofthecorrelation(z2230.124,P=0.001,贮=26.305,P=0.001).ConclusionsTheclinicalevaluationofbreastcancerneoadjuvantch
3、辅助化疗的临床评价与病理评价存在统计学相关性。硕士研究生:范兴哲(法医学)指导教师:赵鹏教授关键词:乳腺癌;新辅助化疗;疗效评价2万方数据AbstractIUllIIlUIlllIlllUIY2738629ObjectiveToinvestigatethedifferencesbetweenbreastcancerneoadjuvantchemotherapy(NAC)beforeandafter,withintheparameterofER,PR,HER一2,飚一67,P53andpathologicalc
4、hangesingradingMPMethodsWecollecttheimplementationof210casesofbreastcancertoneoadjuvantchemotherapyinShandongLiaochengPeople‘SHospitalfromJanuary2009toDecember2012.BeforeneoadjuvantchemotherapyunderwentcoreneedlebiopsyAfter2-4cyclesofchemotherapywetraderadi
5、calmastectomyorbreast·conservingsurgery.Bothbeforeandafterneoadjuvantchemotherapyforbreastprimarytumorclinicalexamination,breastx—rayexamination,accordingtotheResponseEvaluationCriteriainSolidTumors(RECIST,version1.1)oftheprimarytumorinbreastcancerclinicale
6、valuationofefficacy.Inthesametime,weevaluatethepathologicalefficacyaccordingtoMillerandPayne(MP)gradingsystem.Results1)210casesafterNAC,completeremission3cases,124casesofpartialremission,stablediseasein42cases,11casesofdiseaseprogression.Thetotaleffectivera
7、teWas74.7%.2)MPclassification:13cases1,35cases2,30cases3,87cases4and45cases5.3)NACforER,PR,HER-2,Ki一67andP53expressionstatushasnoeffect.ER,HER-2,P53negativeexpressionefficiencyandpositivedifferenceWasstatisticallysignificant(P<0.05).4)Clinicalbreastexaminat
8、ionandX-rayexaminationofrelevantclinicalandpathologicalevaluationofastatisticalevaluationofthecorrelation(z2230.124,P=0.001,贮=26.305,P=0.001).ConclusionsTheclinicalevaluationofbreastcancerneoadjuvantch
此文档下载收益归作者所有